本帖最后由 老马 于 2012-1-13 21:20 编辑 : i2 N" J0 I1 \7 l7 Q+ O; b
) X, G5 n7 G5 R; N4 g爱必妥和阿瓦斯丁的比较
! k1 B. G. Z6 T) [# ~3 T% i
8 P* R8 v5 J, G7 Q! F5 N& z
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
0 g7 m: G/ O# o! T$ x+ N
* L8 M/ w% i8 ~0 \3 Z
, T U6 {6 X$ E* d8 I! u$ C [
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/! w, h3 t4 d+ Y' j3 C
==================================================
9 ^7 e2 X/ j7 VOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) j1 f5 f) t7 a
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
& {* e( k! V: Q1 f% HResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
1 T+ T% A( i9 u9 c
|